Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Jul;26(7):e1285.
doi: 10.1002/onco.13781. Epub 2021 Apr 28.

Regarding the Article by Rugo et al

Sarah Badaoui  1 , Andrew Rowland  1 , Michael J Sorich  1 , Ashley M Hopkins  1
Affiliations
Comment

Regarding the Article by Rugo et al

Sarah Badaoui et al. Oncologist. 2021 Jul.

Abstract

This letter to the editor highlights additional analyses to add to the recently reported study by Rugo et al., regarding abemaciclib treatment for HR+/HER2− breast cancer.

PubMed Disclaimer

Comment in

  • In Reply.
    Rugo HS, Huober J, Garcia-Saenz JA, Masuda N, Sohn JH, Andre VAM, Barriga S, Cox J, Goetz M. Rugo HS, et al. Oncologist. 2021 Jul;26(7):e1286-e1287. doi: 10.1002/onco.13782. Epub 2021 Apr 19. Oncologist. 2021. PMID: 33826783 Free PMC article.

Comment on

References

    1. Rugo HS, Huober J, García‐Sáenz JA et al. Management of abemaciclib‐associated adverse events in patients with hormone receptor–positive, human epidermal growth receptor 2–negative advanced breast cancer: Safety analysis of MONARCH 2 and MONARCH 3. The Oncologist 2021;26:e53–e65. - PMC - PubMed
    1. McAndrew NP, Dickson MA, Clark AS et al. Early treatment‐related neutropenia predicts response to palbociclib. Br J Cancer 2020;123:912–918. - PMC - PubMed
    1. Van Cutsem E, Tejpar S, Vanbeckevoort D et al. Intrapatient cetuximab dose escalation in metastatic colorectal cancer according to the grade of early skin reactions: The randomized EVEREST study. J Clin Oncol 2012;30:2861–2868. - PubMed
    1. Sabanathan D, Zhang A, Fox P et al. Dose individualization of sunitinib in metastatic renal cell cancer: Toxicity‐adjusted dose or therapeutic drug monitoring. Cancer Chemother Pharmacol 2017;80:385–393. - PubMed

LinkOut - more resources